Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update

August 8, 2013 |

1 min read

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAWRENCEVILLE, N.J., Aug. 8, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2013 and an update from its retrospective analysis of the clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.

Hey, check out all the research scientist jobs. Post your resume today!

Earnings

MORE ON THIS TOPIC

AbbVie's office in South San Francisco, California

Cancer

AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B

July 10, 2025

·

1 min read

·

Dan Samorodnitsky

Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs

Infectious disease

Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership

July 10, 2025

·

2 min read

·

Tristan Manalac

Fund raising Capital Donation. Funds Support Concept. Fundraising. Collecting donations in jar.

Series B

Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform

July 10, 2025

·

2 min read

·

Tristan Manalac

A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.

Gene therapy

AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M

July 9, 2025

·

1 min read

·

Dan Samorodnitsky